Vaxart, Inc.

Business to supply a detailed overview of its norovirus clinical system

Webcast to be held on March 28, 2023 at 1:00 p.m. ET

SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT) currently announced it will host a important opinion leader video webcast on the overall health and financial influence and illness burden for norovirus on Tuesday, March 28, 2023 at 1:00 p.m. ET.

The webcast will function presentations by prominent norovirus illness specialists Jan Vinjé, Ph.D., Head, National Calicivirus Laboratory, Centers for Illness Handle &amp Prevention, and Sarah Bartsch, Project Director, Public Wellness Informatics, Computational, and Operations Analysis, Analysis Foundation of the City University of New York.

In addition, Vaxart management will supply a detailed overview of the Company’s investigational norovirus oral pill vaccine system, which includes its two present Phase two clinical trials:

• An ongoing Phase two GI.1 norovirus challenge study measuring the efficacy and security of our norovirus vaccine candidate. The study is also developed to recognize a correlate of protection amongst immune responses to the vaccine and a reduction in threat of norovirus infection and / or extreme gastroenteritis. The Business expects to report topline information from this study in Q3 2023.

• A Phase two dose-ranging study of Vaxart’s bivalent norovirus oral vaccine candidate is developed to recognize a vaccine dose for a possible Phase three clinical trial. The Business expects to report topline information from this study in mid-2023.

To register for the webcast, please click right here. A replay of the webcast will be obtainable on the Company’s web site at www.vaxart.com following the conclusion of the occasion.

About the KOLs

Jan Vinjé, Ph.D.
Dr. Vinjé is head of the National Calicivirus Laboratory and Director of CaliciNet at the Centers for Illness Handle and Prevention (CDC) in Atlanta, GA. Dr. Vinjé received his Ph.D. degree at the University of Utrecht, the Netherlands, in 1999. Following getting a postdoctoral fellowship and an appointment as analysis assistant professor at the University of North Carolina in Chapel Hill, he joined CDC in 2006. More than the previous ten years, he has served on numerous system advisory committees from numerous European analysis projects (FP6, FP7). He is serving as technical specialist on the norovirus subcommittee of the National Advisory Committee on Microbiological Criteria for Foods and is a member of the International Committee on Taxonomy of Viruses study groups on Caliciviridae (chair as of 2014) and Astroviridae. He is at present a member of the editorial board of the Journal of Clinical Microbiology and associate editor of the journal Meals and Environmental Virology, and he serves as an ad hoc reviewer for a number of higher-influence journals. Dr. Vinjé has published more than one hundred peer-reviewed publications and numerous book chapters. His analysis interests incorporate all elements of viral gastrointestinal illness, which includes detection, characterization, and prevention and handle of norovirus infections.

Story continues

Sarah M. Bartsch, MPH
Ms. Bartsch is a Project Director and Senior Analyst with Public Wellness Informatics, Computational, and Operations Analysis (PHICOR), the Artificial Intelligence, Modeling, and Informatics for Nutrition Guidance and Systems (AIMINGS) Center, and the Center for Sophisticated Technologies and Communication in Wellness (CATCH), headquartered at the City University of New York (CUNY) Graduate College of Public Wellness and Wellness Policy. She has been a aspect of the group because August of 2009 and has more than a decade of knowledge employing systems approaches and building mathematical and computational models to help a wide variety of choice makers in public overall health. Bartsch has authored more than 95 scientific publications, which includes extra than 30 as initially author.

About Vaxart 
Vaxart is a clinical-stage biotechnology firm building a variety of oral recombinant vaccines primarily based on its proprietary delivery platform. Vaxart vaccines are developed to be administered employing tablets that can be stored and shipped with out refrigeration and get rid of the threat of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is appropriate to provide recombinant vaccines, positioning the firm to create oral versions of at present marketed vaccines and to style recombinant vaccines for new indications. Vaxart’s improvement applications at present incorporate pill vaccines developed to guard against norovirus, coronavirus, seasonal influenza, and respiratory syncytial virus (RSV), as properly as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s initially immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technologies and creations for oral vaccination employing adenovirus and TLR3 agonists.

Note With regards to Forward-Searching Statements
This press release includes forward-searching statements that involve substantial dangers and uncertainties. All statements, other than statements of historical information, integrated in this press release with regards to Vaxart’s approach, prospects, plans and objectives, outcomes from preclinical and clinical trials, commercialization agreements and licenses, and beliefs and expectations of management are forward-searching statements. These forward-searching statements may well be accompanied by such words as “must,” “think,” “could,” “possible,” “will,” “anticipated,” “anticipate,” “strategy,” and other words and terms of equivalent which means. Examples of such statements incorporate, but are not restricted to, statements relating to Vaxart’s capability to create and commercialize its item candidates, which includes its vaccine booster merchandise Vaxart’s expectations with regards to clinical outcomes and trial information and Vaxart’s expectations with respect to the effectiveness of its item candidates. Vaxart may well not basically realize the plans, carry out the intentions, or meet the expectations or projections disclosed in the forward-searching statements, and you must not spot undue reliance on these forward-searching statements. Actual outcomes or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-searching statements. Several critical variables could trigger actual outcomes or events to differ materially from the forward-searching statements that Vaxart tends to make.

Please also refer to the dangers described in the “Danger Variables” sections of Vaxart’s Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-searching statements, except as needed by law.

Contacts

Investor Relations:

Andrew Blazier

FINN Partners

IR@vaxart.com

(646) 871-8486